ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P25-17 Addition of New Drugs to the Hepatitis C Second Generation Antivirals Prior Authorization (PA) with Quantity Limit (QL) Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2017
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 3121 - 3130 လၢ 3273 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P28-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hereditary Angioedema
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P26-17 New Drug-Related Prior Authorization (PA) Criteria: Urea Cycle Disorders
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P27-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Antifungal Agents
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-17 Provider Services Extended Hours and Callback Technology
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 23, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P24-17 AOR No Longer Required for Submission of Organization Determinations for Platinum Blue Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 18, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P23-17 Change to Administration of Interpreter Services for MHCP Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 16, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP10-17 Implementation of New Utilization Management Platform
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 15, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P22-17 Identified Claims Processing Issues Grid
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 10, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP9-17 Change to Certification of Need Form for Special Transportation Services
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 09, 2017